Dental and Medical Problems

Dent Med Probl
Impact Factor (IF 2023) – 2.7
Journal Citation Indicator (JCI 2023) - 1.06
Scopus CiteScore (2023) – 4.0 (CiteScore Tracker – 4.9)
Index Copernicus (ICV 2023) – 181.00
MNiSW – 70 pts
ISSN 1644-387X (print)
ISSN 2300-9020 (online)
Periodicity – bimonthly


 

Download original text (EN)

Dental and Medical Problems

2020, vol. 57, nr 3, July-September, p. 295–304

doi: 10.17219/dmp/120991

Publication type: review

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Pharmacological and non-pharmacological management of burning mouth syndrome: A systematic review

Leczenie farmakologiczne i niefarmakologiczne zespołu pieczenia jamy ustnej – przegląd piśmiennictwa

Ayman Antoun Reyad1,A,B,D,E, Raafat Mishriky2,A,C,D, Eriny Girgis3,A,C,D

1 School of Pharmacy, University of Wolverhampton, UK

2 Old Age Psychiatry, Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK

3 Community Dental Service, Coventry and Warwickshire Partnership NHS Trust, Coventry, UK

Abstract

Burning mouth syndrome (BMS) is idiopathic chronic oral pain, associated with depression, anxiety and pain symptoms. The BMS symptoms include a burning sensation in the tongue and/or other oral mucosa with no underlying medical or dental reasons. As many BMS patients suffer from psychiatric comorbidities, several psychotropic drugs are included in the management of BMS, reducing the complaint, while managing anxiety, depression and pain disorders. In this review, a search of the published literature regarding the management of BMS was conducted. We discuss the BMS etiology, clinically associated symptoms and available treatment options. The current evidence supports some BMS interventions, including alpha-lipoic acid (ALA), clonazepam, capsaicin, and low-level laser therapy (LLLT); however, there is a lack of robust scientific evidence, and large-scale clinical trials with long follow-up periods are needed to establish the role of these BMS management options. This knowledge could raise the awareness of dentists, psychiatrists and general practitioners about these challenges and the available kinds of treatment to improve multidisciplinary management for better health outcomes.

Key words

burning mouth syndrome, neuropathic pain, orofacial pain, clonazepam, oral conditions

Słowa kluczowe

zespół pieczenia jamy ustnej, ból neuropatyczny, ból twarzoczaszki, klonazepam, warunki w jamie ustnej

References (117)

  1. Grushka M, Ching V. Preliminary exploration of burning mouth and burning feet: Is there a common etiology? Pain Res Manag. 2005;10(3):166–167.
  2. Kisely S, Forbes M, Sawyer E, Black E, Lalloo R. A systematic review of randomized trials for the treatment of burning mouth syndrome. J Psychosom Res. 2016;86:39–46.
  3. Sinding C, Gransjøen AM, Schlumberger G, Grushka M, Frasnelli J, Singh PB. Grey matter changes of the pain matrix in patients with burning mouth syndrome. Eur J Neurosci. 2016;43(8):997–1005.
  4. Almoznino G, Benoliel R, Sharav Y, Haviv Y. Sleep disorders and chronic craniofacial pain: Characteristics and management possibilities. Sleep Med Rev. 2017;33:39–50.
  5. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
  6. Asplund R. Sleep, nocturia and the burning mouth syndrome (BMS) in the elderly. Sleep Hypnos. 2006;8(1):6–11.
  7. Prakash S, Ahuja S, Rathod C. Dopa responsive burning mouth syndrome: Restless mouth syndrome or oral variant of restless legs syndrome? J Neurol Sci. 2012;320(1–2):156–160.
  8. Corsalini M, Di Venere D, Pettini F, Lauritano D, Petruzzi M. Temporomandibular disorders in burning mouth syndrome patients: An observational study. Int J Med Sci. 2013;10(12):1784–1789.
  9. Jääskeläinen SK. Pathophysiology of primary burning mouth syndrome. Clin Neurophysiol. 2012;123(1):71–77.
  10. Kim Y, Kim HI, Kho HS. Characteristics of men and premenopausal women with burning mouth symptoms: A case-control study. Headache. 2014;54(5):888–898.
  11. Mitsikostas DD, Ljubisavljevic S, Deligianni CI. Refractory burning mouth syndrome: Clinical and paraclinical evaluation, comorbidities, treatment and outcome. J Headache Pain. 2017;18(1):40–45.
  12. Dangore-Khasbage S, Khairkar PH, Degwekar SS, et al. Prevalence of oral mucosal disorders in institutionalized and non-institutionalized psychiatric patients: A study from AVBR hospital in Central India. J Oral Sci. 2012;54(1):85–91.
  13. Kossioni AE, Kossionis GE, Polychronopoulou A. Self-reported oral complaints in older mentally ill patients. Geriatr Gerontol Int. 2013;13(2):358–364.
  14. Pajukoski H, Meurman JH, Halonen P, Sulkava R. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92(6):641–649.
  15. Maltsman-Tseikhin A, Moricca P, Niv D. Burning mouth syndrome: Will better understanding yield better management? Pain Pract. 2007;7(2):151–162.
  16. Heckmann SM, Heckmann JG, HiIz MJ, et al. Oral mucosal blood flow in patients with burning mouth syndrome. Pain. 2001;90(3):281–286.
  17. Eliav E. Altered structure and function in hippocampus and medial frontal cortex in patients with burning mouth syndrome. Pain. 2014;155(8):1424–1425.
  18. Penza P, Majorana A, Lombardi R, et al. “Burning tongue” and “burning tip”: The diagnostic challenge of the burning mouth syndrome. Clin J Pain. 2010;26(6):528–532.
  19. Albuquerque RJ, de Leeuw R, Carlson CR, Okeson JP, Miller CS, Andersen AH. Cerebral activation during thermal stimulation of patients who have burning mouth disorder: An fMRI study. Pain. 2006;122(3):223–234.
  20. Forssell H, Jääskeläinen S, Tenovuo O, Hinkka S. Sensory dysfunction in burning mouth syndrome. Pain. 2002;99(1–2):41–47.
  21. Koike K, Shinozaki T, Hara K, et al. Immune and endocrine function in patients with burning mouth syndrome. Clin J Pain. 2014;30(2):168–173.
  22. Guimarães ALS, de Sá AR, Victoria JMN, de Fátima Correia-Silva J, Gomez MV, Gomez RS. Interleukin-1beta and serotonin transporter gene polymorphisms in burning mouth syndrome patients. J Pain. 2006;7(9):654–658.
  23. Tokura T, Kimura H, Ito M, et al. Temperament and character profiles of patients with burning mouth syndrome. J Psychosom Res. 2015;78(5):495–498.
  24. de Souza FTA, Teixeira AL, Amaral TMP, et al. Psychiatric disorders in burning mouth syndrome. J Psychosom Res. 2012;72(2):142–146.
  25. Takenoshita M, Sato T, Kato Y, et al. Psychiatric diagnoses in patients with burning mouth syndrome and atypical odontalgia referred from psychiatric to dental facilities. Neuropsychiatr Dis Treat. 2010;6:699–705.
  26. Matthews RW, Paterson AJ, Scully C. Burning mouth syndrome: Patients’ views. Med Sci Res. 1992;20(22):837–839.
  27. Schiavone V, Adamo D, Ventrella G, et al. Anxiety, depression, and pain in burning mouth syndrome: First chicken or egg? Headache. 2012;52(6):1019–1025.
  28. Coon EA, Laughlin RS. Burning mouth syndrome in Parkinson’s disease: Dopamine as cure or cause? J Headache Pain. 2012;13(3):255–257.
  29. Hagelberg N, Forssell H, Rinne JO, et al. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain. 2003;101(1–2):149–154.
  30. Cochrane Training. Cochrane Information Specialists’ Handbook. https://training.cochrane.org/resource/cochrane-information-specialists-handbook. Updated 2020. Accessed on April 21, 2020.
  31. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–1012.
  32. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol. 1997;29(3):315–331.
  33. Carbone M, Pentenero M, Carrozzo M, Ippolito A, Gandolfo S. Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: A double-blind, randomized, placebo-controlled study. Eur J Pain. 2009;13(5):492–496.
  34. López-Jornet P, Camacho-Alonso F, Leon-Espinosa S. Efficacy of alpha lipoic acid in burning mouth syndrome: A randomized, placebo-treatment study. J Oral Rehabil. 2009;36(1):52–57.
  35. Marino R, Torretta S, Capaccio P, Pignataro L, Spadari F. Different therapeutic strategies for burning mouth syndrome: Preliminary data. J Oral Pathol Med. 2010;39(8):611–616.
  36. Femiano F, Gombos F, Scully C, Busciolano M, De Luca P. Burning mouth syndrome (BMS): Controlled open trial of the efficacy of alpha-lipoic acid (thioctic acid) on symptomatology. Oral Dis. 2000;6(5):274–277.
  37. Femiano F, Scully C. Burning mouth syndrome (BMS): Double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med. 2002;31(5):267–269.
  38. Femiano F, Scully C, Gombos F. Idiopathic dysgeusia; an open trial of alpha lipoic acid (ALA) therapy. Int J Oral Maxillofac Surg. 2002;31(6):625–628.
  39. Femiano F. Burning mouth syndrome (BMS): An open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other the­rapies. Minerva Stomatol. 2002;51(9):405–409.
  40. Femiano F, Gombos F, Scully C. Burning mouth syndrome: Open trial of psychotherapy alone, medication with alpha-lipoic acid (thioctic acid), and combination therapy. Med Oral. 2004;9(1):8–13.
  41. López-D’Alessandro E, Escovich L. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of burning mouth syndrome: A randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal. 2011;16(5):e635–e640.
  42. Palacios-Sánchez B, Moreno-López LA, Cerero-Lapiedra R, Llamas-Martínez S, Esparza-Gómez G. Alpha lipoic acid efficacy in burning mouth syndrome. A controlled clinical trial. Med Oral Patol Oral Cir Bucal. 2015;20(4):e435–e440.
  43. Cavalcanti DR, da Silveira FRX. Alpha lipoic acid in burning mouth syndrome – a randomized double-blind placebo-controlled trial. J Oral Pathol Med. 2009;38(3):254–261.
  44. Femiano F, Gombos F, Scully C. Burning mouth syndrome: The efficacy of lipoic acid on subgroups. J Eur Acad Dermatol Venereol. 2004;18(6):676–678.
  45. Barbosa NG, Goes Gonzaga AK, de Sena Fernandes LL, et al. Evaluation of laser therapy and alpha-lipoic acid for the treatment of burning mouth syndrome: A randomized clinical trial. Lasers Med Sci. 2018;33(6):1255–1262.
  46. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia, PA: Wolters Kluvwer; 2017.
  47. Gremeau-Richard C, Woda A, Navez ML, et al. Topical clonazepam in stomatodynia: A randomised placebo-controlled study. Pain. 2004;108(1–2):51–57.
  48. Heckmann SM, Kirchner E, Grushka M, Wichmann MG, Hummel T. A double-blind study on clonazepam in patients with burning mouth syndrome. Laryngoscope. 2012;122(4):813–816.
  49. Rodríguez de Rivera Campillo E, López-López J, Chimenos-Küstner E. Response to topical clonazepam in patients with burning mouth syndrome: A clinical study. Bull Group Int Rech Sci Stomatol Odontol. 2010;49(1):19–29.
  50. Barker KE, Batstone MD, Savage NW. Comparison of treatment moda­lities in burning mouth syndrome. Aust Dent J. 2009;54(4):300–305; quiz 396.
  51. Hens MJ, Alonso-Ferreira V, Villaverde-Hueso A, Abaitua I, Posada de la Paz M. Cost-effectiveness analysis of burning mouth syndrome therapy. Community Dent Oral Epidemiol. 2012;40(2):185–192.
  52. Guarneri F, Guarneri C, Marini H. Contribution of neuroinflammation in burning mouth syndrome: Indications from benzodiazepine use. Dermatol Ther. 2008;21(Suppl 2):S21–S24.
  53. Petruzzi M, Lauritano D, De Benedittis M, Baldoni M, Serpico R. Systemic capsaicin for burning mouth syndrome: Short-term results of a pilot study. J Oral Pathol Med. 2004;33(2):111–114.
  54. Lauritano D, Petruzzi M, Baldoni M. Preliminary protocol for systemic administration of capsaicin for the treatment of the burning mouth syndrome [in Italian]. Minerva Stomatol. 2003;52(6):273–278.
  55. Toida M, Kato K, Makita H, et al. Palliative effect of lafutidine on oral burning sensation. J Oral Pathol Med. 2009;38(3):262–268.
  56. Fleuret C, Le Toux G, Morvan J, et al. Use of selective serotonin reuptake inhibitors in the treatment of burning mouth syndrome. Dermatology. 2014;228(2):172–176.
  57. Gruden SJP, Vidas M, Gruden V. Stomatodynia – an indication for antidepressant therapy. Soc Psihijatrija. 2004;32(2):90–93.
  58. Yamazaki Y, Hata H, Kitamori S, Onodera M, Kitagawa Y. An open-label, noncomparative, dose escalation pilot study of the effect of paroxetine in treatment of burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(1):e6–e11.
  59. Ginsberg DL. Eating disorders over the lifecycle: Diagnosis and treatment. Primary Psych. 2003;10(6):15.
  60. Loldrup D, Langemark M, Hansen HJ, Olesen J, Bech P. Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. Psychopharmacology (Berl). 1989;99(1):1–7.
  61. Mignogna MD, Adamo D, Schiavone V, Ravel MG, Fortuna G. Burning mouth syndrome responsive to duloxetine: A case report. Pain Med. 2011;12(3):466–469.
  62. Kim YD, Lee JH, Shim JH. Duloxetine in the treatment of burning mouth syndrome refractory to conventional treatment: A case report. J Int Med Res. 2014;42(3):879–883.
  63. Pekiner FN, Gumru B, Ozbayrak S. Efficacy of moclobemide in burning mouth syndrome: A nonrandomized, open-label study. J Orofac Pain. 2008;22(2):146–152.
  64. Pae CU. Milnacipran for chronic pain in the orofacial region. Clin Neuropharmacol. 2010;33(5):270.
  65. Kato Y, Sato T, Katagiri A, et al. Milnacipran dose-effect study in patients with burning mouth syndrome. Clin Neuropharmacol. 2011;34(4):166–169.
  66. Ito M, Kimura H, Yoshida K, Kimura Y, Ozaki N, Kurita K. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. Clin Neuropharmacol. 2010;33(2):79–83.
  67. Sugimoto K. The dubious effect of milnacipran for the treatment of burning mouth syndrome. Clin Neuropharmacol. 2011;34(4):170–173.
  68. Ukai K, Kimura H, Arao M, et al. Effectiveness of low-dose milnacipran for a patient suffering from pain disorder with delusional disorder (somatic type) in the orofacial region. Psychogeriatrics. 2013;13(2):99–102.
  69. Ferensztajn E, Łojko D, Rybakowski J. Burning mouth syndrome: Pathogenic and therapeutic concepts. Psychiatr Pol. 2013;47(6):973–988.
  70. Ueda N, Kodama Y, Hori H, et al. Two cases of burning mouth syndrome treated with olanzapine. Psychiatry Clin Neurosci. 2008;62(3):359–361.
  71. Umezaki Y, Takenoshita M, Toyofuku A. Low-dose aripiprazole for refractory burning mouth syndrome. Neuropsychiatr Dis Treat. 2016;12:1229–1231.
  72. Demarosi F, Tarozzi M, Lodi G, Canegallo L, Rimondini L, Sardella A. The effect of levosulpiride in burning mouth syndrome. Minerva Stomatol. 2007;56(1-2):21–26.
  73. Maina G, Vitalucci A, Gandolfo S, Bogetto F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: A single-blind study. J Clin Psychiatry. 2002;63(1):38–43.
  74. Stuginski-Barbosa J, Rodrigues GGR, Bigal ME, Speciali JG. Burning mouth syndrome responsive to pramipexol. J Headache Pain. 2008;9(1):43–45.
  75. Ito M, Tokura T, Yoshida K, et al. Five patients with burning mouth syndrome in whom an antidepressant (serotonin-noradrenaline reuptake inhibitor) was not effective, but pregabalin markedly relieved pain. Clin Neuropharmacol. 2015;38(4):158–161.
  76. White TL, Kent PF, Kurtz DB, Emko P. Effectiveness of gabapentin for treatment of burning mouth syndrome. Arch Otolaryngol Head Neck Surg. 2004;130(6):786–788.
  77. Heckmann SM, Heckmann JG, Ungethüm A, Hujoel P, Hummel T. Gabapentin has little or no effect in the treatment of burning mouth syndrome – results of an open-label pilot study. Eur J Neurol. 2006;13(7):e6–e7.
  78. Arbabi-Kalati F, Bakhshani NM, Rasti M. Evaluation of the efficacy of low-level laser in improving the symptoms of burning mouth syndrome. J Clin Exp Dent. 2015;7(4):e524–e527.
  79. Spanemberg JC, López-López J, de Figueiredo MAZ, Cherubini K, Salum FG. Efficacy of low-level laser therapy for the treatment of burning mouth syndrome: A randomized, controlled trial. J Biomed Opt. 2015;20(9):098001.
  80. Spanemberg JC, Segura-Egea JJ, Rodríguez-de Rivera-Campillo E, Jané-Salas E, Salum FG, López-López J. Low-level laser therapy in patients with burning mouth syndrome: A double-blind, randomized, controlled clinical trial. J Clin Exp Dent. 2019;11(2):e162–e169.
  81. Valenzuela S, López-Jornet P. Effects of low-level laser therapy on burning mouth syndrome. J Oral Rehabil. 2017;44(2):125–132.
  82. Bardellini E, Amadori F, Conti G, Majorana A. Efficacy of the photobiomodulation therapy in the treatment of the burning mouth syndrome. Med Oral Patol Oral Cir Bucal. 2019;24(6):e787–e791.
  83. Miziara ID, Filho BCA, Oliveira R, dos Santos RMR. Group psychotherapy: An additional approach to burning mouth syndrome. J Psychosom Res. 2009;67(5):443–448.
  84. Forssell H, Teerijoki-Oksa T, Kotiranta U, et al. Pain and pain behaviour in burning mouth syndrome: A pain diary study. J Orofac Pain. 2012;26(2):117–125.
  85. Lewis AK, Prime SS, Cohen SN. An overview of burning mouth syndrome for the dermatologist. Clin Exp Dermatol. 2016;41(2):119–123.
  86. Raghavan SA, Puttaswamiah RN, Birur PN, Ramaswamy B, Sunny SP. Antidepressant-induced burning mouth syndrome: A unique case. Korean J Pain. 2014;27(3):294–296.
  87. Buchanan JA, Zakrzewska JM. Burning mouth syndrome. BMJ Clin Evid. 2010;2010:1301.
  88. Zakrzewska JM. Multi-dimensionality of chronic pain of the oral cavity and face. J Headache Pain. 2013;14(1):37.
  89. Silvestre FJ, Silvestre-Rangil J, López-Jornet P. Burning mouth syndrome: A review and update. Rev Neurol. 2015;60(10):457–463.
  90. Spanemberg JC, Cherubini K, de Figueiredo MAZ, Yurgel LS, Salum FG. Aetiology and therapeutics of burning mouth syndrome: An update. Gerodontology. 2012;29(2):84–89.
  91. Gorsky M, Silverman S Jr., Chinn H. Clinical characteristics and ma­nagement outcome in the burning mouth syndrome. An open study of 130 patients. Oral Surg Oral Med Oral Pathol. 1991;72(2):192–195.
  92. Liu YF, Kim Y, Yoo T, Han P, Inman JC. Burning mouth syndrome: A systematic review of treatments. Oral Dis. 2018;24(3):325–334.
  93. Eryılmaz A, Ayrancı Ü. Burning mouth syndrome: A case presentation [in Turkish]. Anadolu Psikiyatri Derg. 2002;3(3):169–173.
  94. Grinspan D, Fernández Blanco G, Allevato MA, Stengel FM. Burning mouth syndrome. Int J Dermatol. 1995;34(7):483–487.
  95. Klasser GD, Epstein JB, Villines D, Utsman R. Burning mouth syndrome: A challenge for dental practitioners and patients. Gen Dent. 2011;59(3):210–220;quiz 221–222.
  96. Jørgensen MR, Pedersen AML. Analgesic effect of topical oral capsaicin gel in burning mouth syndrome. Acta Odontol Scand. 2017;75(2):130–136.
  97. Silvestre FJ, Silvestre-Rangil J, Tamarit-Santafé C, Bautista D. Application of a capsaicin rinse in the treatment of burning mouth syndrome. Med Oral Patol Oral Cir Bucal. 2012;17(1):e1–e4.
  98. Fenelon M, Quinque E, Arrive E, Catros S, Fricain JC. Pain-relieving effects of clonazepam and amitriptyline in burning mouth syndrome: A retrospective study. Int J Oral Maxillofac Surg. 2017;46(11):1505–1511.
  99. de Castro LA, Ribeiro-Rotta RF. The effect of clonazepam mouthwash on the symptomatology of burning mouth syndrome: An open pilot study. Pain Med. 2014;15(12):2164–2165.
  100. Zoric B, Jankovic L, Kuzmanovic Pficer J, Zidverc-Trajkovic J, Mijajlovic M, Stanimirovic D. The efficacy of fluoxetine in BMS – a cross-over study. Gerodontology. 2018;35(2):123–128.
  101. Tammiala-Salonen T, Forssell H. Trazodone in burning mouth pain: A placebo-controlled, double-blind study. J Orofac Pain. 1999;13(2):83–88.
  102. Sardella A, Lodi G, Demarosi F, Tarozzi M, Canegallo L, Carrassi A. Hypericum perforatum extract in burning mouth syndrome: A randomized placebo-controlled study. J Oral Pathol Med. 2008;37(7):395–401.
  103. Varoni EM, Lo Faro AF, Lodi G, Carrassi A, Iriti M, Sardella A. Melatonin treatment in patients with burning mouth syndrome: A triple-blind, placebo-controlled, crossover randomized clinical trial. J Oral Facial Pain Headache. 2018;32(2):178–188.
  104. Treldal C, Jacobsen CB, Mogensen S, et al. Effect of a local anesthetic lozenge in relief of symptoms in burning mouth syndrome. Oral Dis. 2016;22(2):123–131.
  105. Sardella A, Uglietti D, Demarosi F, Lodi G, Bez C, Carrassi A. Benzydamine hydrochloride oral rinses in management of burning mouth syndrome. A clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(6):683–686.
  106. Grémeau-Richard C, Dubray C, Aublet-Cuvelier B, Ughetto S, Woda A. Effect of lingual nerve block on burning mouth syndrome (stomatodynia): A randomized crossover trial. Pain. 2010;149(1):27–32.
  107. Jurisic Kvesic A, Zavoreo I, Basic Kes V, et al. The effectiveness of acupuncture versus clonazepam in patients with burning mouth syndrome. Acupunct Med. 2015;33(4):289–292.
  108. Zavoreo I, Vučićević Boras V, Zadravec D, et al. The significance of brain transcranial sonography in burning mouth syndrome: A pilot study. Acta Stomatol Croat. 2017;51(1):48–59.
  109. Sugaya NN, da Silva EFP, Kato IT, Prates R, de Barros Gallo C, Pellegrini VD. Low intensity laser therapy in patients with burning mouth syndrome: A randomized, placebo-controlled study. Braz Oral Res. 2016;30(1):e108.
  110. Antonić R, Brumini M, Vidovic I, Muhvić Urek M, Glazar I, Pezelj-Ribarić S. The effects of low level laser therapy on the management of chronic idiopathic orofacial pain: Trigeminal neuralgia, temporomandibular disorders and burning mouth syndrome. Medicina Flum. 2017;53(1):61–67.
  111. dos Santos LdFC, de Andrade SC, Nogueira GEC, Leão JC, de Freitas PM. Phototherapy on the treatment of burning mouth syndrome: A prospective analysis of 20 cases. Photochem Photobiol. 2015;91(5):1231–1236.
  112. dos Santos LdFC, Carvalho AdAT, Leão JC, da Cruz Perez DE, de Castro JFL. Effect of low-level laser therapy in the treatment of burning mouth syndrome: A case series. Photomed Laser Surg. 2011;29(12):793–796.
  113. Brailo V, Bosnjak A, Vucicevic Boras V, Kvesic Jurisic A, Pelivan I, Kraljevic-Simunkovic S. Laser acupuncture in the treatment of burning mouth syndrome: A pilot study. Acupunct Med. 2013;31(4):453–454.
  114. Arduino PG, Cafaro A, Garrone M, et al. A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome. Lasers Med Sci. 2016;31(4):811–816.
  115. Sikora M, Včev A, Siber S, Vučićević Boras V, Rotim Ž, Matijević M. The efficacy of low-level laser therapy in burning mouth syndrome – a pilot study. Acta Clin Croat. 2018;57(2):312–315.
  116. Bergdahl J, Anneroth G, Perris H. Cognitive therapy in the treatment of patients with resistant burning mouth syndrome: A controlled study. J Oral Pathol Med. 1995;24(5):213–215.
  117. Komiyama O, Nishimura H, Makiyama Y, et al. Group cognitive-behavioral intervention for patients with burning mouth syndrome. J Oral Sci. 2013;55:17–22.
© Wroclaw Medical University